<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111027">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005965</url>
  </required_header>
  <id_info>
    <org_study_id>CCR2943</org_study_id>
    <nct_id>NCT02005965</nct_id>
  </id_info>
  <brief_title>Low Rectal Cancer Study (MERCURY II)</brief_title>
  <acronym>MERCURY II</acronym>
  <official_title>The Low Rectal Cancer Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pelican Cancer Foundation (www.pelicancancer.org)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MERCURY Study demonstrated the accuracy, feasibility and reproducibility of Magnetic
      Resonance Imaging (MRI) to stage rectal cancer in a prospective, multidisciplinary,
      multi-centre study. However, there were differences in patient outcome, dependent upon the
      position of the tumour in the rectum and its height above the anal verge. Whilst the outcome
      was excellent for patients who underwent an anterior resection, the outcome, based upon
      margin involvement and quality of the specimen, was poor for patients who underwent an
      abdomino-perineal excision for low rectal cancer.

      It is proposed that accurate MRI staging pre-operatively will allow the correct patients to
      receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the
      resection margins appear threatened so that the operation can be modified to take this into
      account. The primary aims of the Low Rectal Cancer Study (MERCURY II) are to assess the rate
      of CRM positivity rate in low rectal cancer and to assess the difference in global quality
      of life at two years post surgery in patients according to plane of surgery with or without
      sphincter preservation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to reduce the positive margin rate of 30% to around 15%. The study
      is an international multicentre, prospective, observational study, whereby patients with
      biopsy-proven low-rectal cancer (lower edge of the tumour &lt; 6cms from the anal verge on
      MRI), will be recruited from participating centres, having given informed, written consent.
      Data from the radiology, surgical and pathological aspects will be collected and analysed
      centrally at the Royal Marsden Hospital. The patient's medical records will be reviewed for
      five years post surgery, and the patients will also be followed up by quality of life
      questionnaires. This project aims to show that in low rectal cancer, improved local control
      and survival can be achieved through a reduction in the involved CRM rates by MRI-planned
      surgery and selective pre-operative therapy. It also aims to assess the ability to predict
      disease recurrence and to provide an assessment of disease-free survival and overall
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To assess the rate of CRM positivity rate in low rectal cancer.</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare patient reported outcomes in patients according to plane of surgery with or without sphincter preservation.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the clinical and radiological factors influencing the decision by surgeons to carry out Anterior Resections, APE or extralevator APE.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to local recurrence, disease-free and overall survival between patients undergoing different types of surgery.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of imaging and pathology staging assessment, patient characteristics and complication rates, between different types of surgery and surgical approaches.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of potential associations between imaging and pathology assessment of radial and distal margins, neo-adjuvant chemoradiotherapy, perineal complications and sphincter preservation rates.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">495</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Adenocarcinoma, Mucinous</condition>
  <condition>Carcinoma</condition>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms, Cystic, Mucinous, and Serous</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Neoplasms by Site</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Intestinal Diseases</condition>
  <condition>Rectal Diseases</condition>
  <arm_group>
    <arm_group_label>Staging and outcomes for patients with Low Rectal Cancer</arm_group_label>
    <description>Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with biopsy proven adenocarcinoma within 6cm of the anal verge confirmed on MRI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to give informed, written consent.

          -  Adults age 18 or over - male or female.

          -  Recently diagnosed with biopsy-proven, primary, low rectal cancer.

          -  No previous therapy for rectal cancer.

        Exclusion Criteria:

          -  Current pregnancy, including ectopic pregnancy.

          -  Previous pelvic/rectal malignancy (excluding carcinoma in-situ).

          -  Previous pelvic radiotherapy.

          -  Previous pelvic floor surgery for faecal incontinence or prolapse.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Moran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pelican Cancer Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina Brown</last_name>
    <phone>0208 915 3694</phone>
    <email>gina.brown@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick Battersby</last_name>
    <phone>01256 314746</phone>
    <email>nick.battersby@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Goebel</last_name>
      <email>thomas.goebel@cra-freelancer.com</email>
    </contact>
    <investigator>
      <last_name>Joachim Strassburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigmar Stelzner</last_name>
      <email>Stelzner-Si@khdf.de</email>
    </contact>
    <investigator>
      <last_name>Sigmar Stelzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Surgical Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Petrovic</last_name>
      <email>jelapetrovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Petrovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Milton Keynes General Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <state>Buckinghamshire</state>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Edwards</last_name>
      <email>Stephanie.Edwards@mkhospital.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anil Hernandes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Hampshire Hospitals NHS Trust (Basingstoke Hospital)</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Battersby</last_name>
      <phone>01256 314746</phone>
      <email>nick.battersby@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Brendan Moran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston General Hospital</name>
      <address>
        <city>Weston-super-Mare</city>
        <state>Somerset</state>
        <zip>BS23 4TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Coles</last_name>
      <phone>01934 881377</phone>
      <phone_ext>5049</phone_ext>
      <email>deborahcoles@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Geoff Pye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Croydon University Hospital</name>
      <address>
        <city>Croydon</city>
        <state>Surrey</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Campbell</last_name>
      <phone>020 8401 3000</phone>
      <phone_ext>5661</phone_ext>
      <email>Yvonne.Campbell@croydonhealth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ibiyemi Olaleye</last_name>
      <phone>020 8401 3000</phone>
      <phone_ext>4761</phone_ext>
      <email>Ibiyemi.Olaleye@croydonhealth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Swift</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital NHS Foundation Trust</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Burgess</last_name>
      <phone>01276 526779</phone>
      <email>carrie.burgess@nhs.net</email>
    </contact>
    <investigator>
      <last_name>David Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess of Wales Hospital</name>
      <address>
        <city>Bridgend</city>
        <state>Wales</state>
        <zip>CF31 1RQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Roche</last_name>
      <phone>02920 615888</phone>
      <phone_ext>6701</phone_ext>
      <email>Lisa.Roche2@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Joanna Hilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoe Davies</last_name>
      <phone>02920746609</phone>
      <email>Zoe.davies7@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury NHS Foundation Trust (Salisbury District Hospital)</name>
      <address>
        <city>Salisbury</city>
        <state>Wiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiliary Dean</last_name>
      <phone>01722 336262</phone>
      <phone_ext>2194</phone_ext>
      <email>Hilary.Dean@salisbury.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Graham Branagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulster Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT16 1RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethna McFerran</last_name>
      <email>ethna.mcferran@setrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Ian McAllister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London &amp; Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Scerri</last_name>
      <phone>0208 915 6067</phone>
      <email>lisa.scerri@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Gina Brown</last_name>
      <phone>0208 661 3964</phone>
      <email>gina.brown@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Gina Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Serbia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=8078</url>
    <description>UKCRN Portfolio</description>
  </link>
  <link>
    <url>http://www.pelicancancer.org/bowel-cancer-research/low-rectal-cancer-study</url>
    <description>Pelican Cancer Foundation website info on this study</description>
  </link>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Low Rectal Cancer</keyword>
  <keyword>MERCURY</keyword>
  <keyword>Cancer</keyword>
  <keyword>CRM</keyword>
  <keyword>Circumferential Margin</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>MRI</keyword>
  <keyword>Radiology</keyword>
  <keyword>Abdominoperineal Excision</keyword>
  <keyword>Anterior Resection</keyword>
  <keyword>Surgery</keyword>
  <keyword>Pathology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Rectal Diseases</mesh_term>
    <mesh_term>Neoplasms, Cystic, Mucinous, and Serous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
